Human lung explants maintained in culture for 7 d incorporate [ 3 H]glucosamine into mucous glycoproteins. Ethanol-precipitable, glucosamine-labeled mucous secretion was measured, and the effects of different pharmacologic agents upon this secretion were investigated. Anaphylaxed human lung generates prostaglandin (PG) synthesis and increased mucous release. Arachidonic acid (AA), PGA 2 , PGD 2 , and PGF 2a significantly increased mucous glycoprotein release, whereas PGE 2 significantly reduced release. Evidence which suggests that lipoxygenase products of AA augment mucous release includes the following: (a) Nonsteroidal anti-inflammatory drugs (NSAID: acetylsalicylic acid and indomethacin) increase mucous release while preventing prostaglandin formation. (b) The increase in mucous release induced by AA or NSAID is additive once the agents are combined. (c) Several nonspecific lipoxygenase inhibitors (eicosa-5,8,11,14-tetraynoic acid; vitamin E; nordihydroguaiaretic acid; and a-naphthol) inhibit mucous release. Three additional lines of evidence directly indicate that monohydroxyeicosatetraenoic acid (HETE) causes increased mucous release: (a) the addition of a mixture of synthetic HETE (24-600 nM) increases mucous release; (b) pure 12-HETE (1-100 nM) also increases mucous release; (c) mucous release is increased synergistically by the combination of HETE and NSIAD.
These data taken together demonstrate that HETE are capable of increasing mucous release and that conditions which may influence HETE production alter mucous release. Thus, although not directly demonstrating HETE production by human airways, the data stronigly suggest that lipoxygenase products of AA in airways may profoundly influence mucous release; and
INTRODUCTION
Hypersecretion of bronchial mucus is a major feature ofmany respiratory diseases and contributes to the morbidity of a large segment of the population. To study the controls of mucous synthesis and secretion, an in vitro model involving the culture of human airways (1) was developed (2) . Human airways may be cultured for extended periods of time and newly synthesized mucous secretion may be analyzed either by autoradiography after pulse labeling (3, 4) or by incorporation of radiolabeled molecules into newly formed mucus (2, 5) . Human airways incorporate sugars, amino sugars, amino acids, and sulfate equally well into glycoproteins. Two glycoproteins are synthesized: one with an apparent molecular weight >7 x 106 and the other -400,000 (2) . Both of these molecules are rich in carbohydrates (80 and 60% of total composition, respectively), have similar charge characteristics of ion-exchange chromatography and by isoelectric focusing, and are formed in equal amounts by airway cultures. Similar molecules may be synthesized by airways ofexperimental animals (6) . Anaphylaxis of human airways increases mucous release, partially due to histamine H-2 receptor stimulation (2). Muscarinic (2, 5) and alpha adrenergic (2) stimulation also increases mucous release, whereas beta adrenergic stimulation has no effect. to contribute to the local regulation of many organ systems. Although the lung is one of the major sites of PG synthesis (7) and inactivation (8, 9) , little is known about their role in mucous secretion. Inhalation of PGF2G by normal humans induces mucous secretion (10) . Similarly, the infusion of PGF2. in dogs in vivo is associated with increased bronchosecretory activity (11) . PG are generated during human lung anaphylaxis (12) (13) (14) and mucous release is enhanced in anaphylaxis (2); therefore, it seemed appropriate to analyze the effect ofPG and other derivatives ofarachidonic acid (AA) on mucous glycoprotein release.
METHODS
Tritiated PGF2a (5,6,8,9,11,12,14,15- 35 -mm tissue culture dishes. The airway explants were maintained in 2.0 ml of CMRL-1066 medium with added bovine insulin (1 ,g/ml), hydrocortisone hemisuccinate (0.1 gg/ml), penicillin (100,g/ ml), streptomycin (100 ,ug/ml), and amphotericin B (0.5 ,g/ml), as described (1) . The culture dishes were placed in a controlled atmosphere chamber and gassed at 10 pounds per square inch (psi) with 50% 02,45% N2, and 5% CO2 for 5 min. The chamber was placed on a rocker platform which rocked at 10 cycle/min, causing the media to flow intermittently over the surface of the explants. The explants were incubated at 37°C for an initial 16-h period.
Radiolabeling of mucous glycoprotein. Mucous glycoproteins may be radiolabeled by incorporating [3H]glucosamine (1 gCi/ml) into the culture medium (2, 3, 5) . After an initial 16-h incubation in the absence of [3H] glucosamine, the cultures were washed twice with CMRL-1066 medium and incubated with [3H]glucosamine for a 16-20-h base-line period (period I). Thereafter, the culture media were harvested, the airways washed twice with 1 ml culture media, and the washings were combined with the harvested supernate. Fresh culture media without [3H]glucosamine were added to the cultures for an additional 4-h period (period II). At the end of period II, the supematant media were harvested, the cultures washed twice, and the washings added to the harvested supemates (2, 5) .
Airway cultures were subsequently recycled through 16-h base-line incubations in [3H]glucosamine (period I), followed by 4-h (period II) incubations in the absence of [3H]-glucosamine, for up to 7 d. The physicochemical characteristics of airways cultured for 3 or 14 d were compared by Sepharose 2B and DEAE-cellulose chromatography as described (2). The labeled glycoproteins were similar as assessed by both size and charge characteristics. Histologic analyses of airways maintained in culture for 7 d revealed a normal appearing mucosa including goblet cells. The submucous glands in these fragments were present in every section and appeared histologically normal throughout the 7-d period; they outnumbered the goblet cells by a considerable margin.
Separation of radiolabeled glycoproteins. The culture media and washes (4 ml, total) from periods II and I were stored at -70°C. 1-ml aliquots were added to 1 ml 95% ethanol, vortexed, and filtered through Metricel membrane filters. The filters were wetted with 1 ml 95% ethanol just before the addition of the culture media-ethanol mixture, and the retained filtrate was washed three times with 1 ml 95% ethanol. The filters were placed in scintillation vials, dried at 1000C for 20 min, and incubated at room temperature for 25 min before the addition of 10 ml Aquasol. The scintillation vials were vortexed and incubated for at least 1 h at room temperature before liquid scintillation counting in a Beckman 9100 scintillation counter (Beckman Instruments, Inc., Mountainside, N. J.).
Effect of pharmacologic agetnts upon the release of mucous glycoproteins. The effect of pharmacologic manipulations on the release of [3H]glucosamine-labeled mucous glycoprotein was determined by adding agents to cultures at the beginning of period II. A ratio of the radiolabeled precipitated counts per minute of period II/period I for each sample was determined and was termed the secretory index. The actual counts per minute and secretory indices of control samples from eight separate lungs cultured for up to 7 d are provided in Table I . Due to the relatively high secretory index observed in day-1 cultures, no experiments were done during the initial cycle. Instead, all experiments were performed on lungs between days 2 and 7 in culture.
The effects of pharmacologic agents were determined by comparing the secretory indices of manipulated samples with matched, unmanipulated, control samples. Thus, each airway culture provided its own base-line period (period I), as well as stimulated period (period II), and the effects of each pharmacologic manipulation could be compared with matched controls. The example provided in Table I indicates the unmanipulated control data with which manipulated samples would be compared.
All unstable pharmacologic agents were prepared immediately before use. Indomethacin was dissolved in 0.1 N sodium carbonate. Eicosa-5,8,11,14-tetraynoic acid (ETYA) was dissolved in dimethylsulfoxide and all the antioxidants were dissolved in methanol. Aspirin was dissolved in ethanol. An aliquot of aspirin in ethanol was taken to dryness at 450C by a stream of N2, redissolved in medium, and immediately added to cultures (15) . The PG were dissolved in 80% ethanol and maintained as 10-mg/ml stock solutions. All the chemicals were diluted to a final concentrationi with medium after going 1696 (18) . The specific identification of the mixture of the HETE contained in the eluate from the thin-layer chromatography was resolved by high-performance liquid chromatography employing a microporasil column (18) . The mixture generated consisted of 5-, 8-, 11-, and 12-HETE. The identification of the HETE was kindly performed by Frank Sun, Ph.D., Upjohn Co.
Statistics. Data will be preseht as the mean±SEM. The n in the tables and figure legends indicates the number of experiments combined to generate the results. In each experiment, between four and eight samples were used to generate each experimental point. The data were analyzed both by Student's t test for unpaired samples and by paired sample t tests, with a P value of <0.05 considered statistically significant.
The results are expressed as percent change from control and represent the comparison of the secretory index (period II/period I) between pharmacologically manipulated samples and matched controls.
RESULTS
Effect of prostaglandins on mucous glycoprotein release. The addition of PG to airway cultures at the onset of period II was analyzed using concentrations of 0.0001-100 ,uM. A number of PG were examined (Table II). PGA2, PGD2, and PGF2n,, significantly increased mucous glycoprotein release at 100-I,M concentrations; PGF1,,, PGI2, and PGE1 tended to increase mucous release, but the results were not statistically significant; and T x B2 was inactive. PGE2 significantly reduced mucous secretion with maximal activity at 1 pAM.
Effect of arachidonic acid on mucous glycoprotein release. AA added to lung tissue is enzymatically converted to the specific PG ordinarily produced (19, 20) . Therefore, the effects on mucous release of adding AA to airways were studied. As shown inrTableIII, AA from 1-100 ,ug/ml induced a dose-related increase in the release of mucus, suggesting that either AA itself or derivatives of AA increase mucous release. Arachitic acid and palmitic acid (both at 100 ug/ml) had no effect on mucous release.
Effect of nonsteroidal anti-inflammatory drugs (NSAID) on mucous glycoprotein release. To examine whether the inhibition of the endogenous generation of PG during period II might have an influence on the secretion of mucus, acetylsalicylic acid (ASA) (100,ug/ml) and indomethacin (10,ug/ml) were studied.
In each of four experiments in which both PG and mucous generation were measured, ASA and indomethacin significantly reduced the formation of PGF2<, and PGE by the airways in culture; however, mucous release was not inhibited but was enhanced (Table IV A) . In a total of 10 experiments with ASA, the release of mucus was increased by 29.4±6.4% (P < 0.01) (Table IV B) . In a total of 13 experiments indomethacin increased mucous release by 28.4±+-7.7% (P < 0.01). Therefore, inhibition of the cyclo-oxygenase enzyme system by NSAID results in an increase in mucous glycoprotein release. These results suggest either that reduction of the inhibitory influence of PGE2 induces increased mucous release or that endogenous AA may become more available for metabolism by the lipoxygenase enzyme system once the cyclo-oxygenase system is impaired. We reasoned that impairing cyclo-oxygenase en- tion of24-600-nM concentrations of HETE at the onset of period II increased mucous release by 8.0-15.7%. Two other hydroxy fatty acids, ricinoleic acid and 12-hydroxystearate in 100-,tM concentrations had no effect on mucous release. In two experiments, the effects of 240 nM HETE upon PGE generation were determined; PGE release was inhibited by 54+4%. In two additional experiments, the effect of 600 nM HETE upon PGF2, generation was examined; 73+16% inhibition was appreciated. Thus, the exogenous addition of a mixture of HETE may also suppress both PGE and PGF2,,, generation by human airways.
The UV-irradiated preparation of HETE may contain sterioisomers which human airways in vivo may never encounter. Therefore, the effect of pure 12-HETE +58.0±11.0Y
* Results represent single representative experiments.
I P < 0.01 compared with control. § P < 0.05 compared with control. "P < 0.001 compared with control.
(1-100 nM) was examined. 12-HETE increased the release of mucus in a dose-related fashion: 1 nM increased mucous release by 22 .7±6.8% (P < 0.05), 10 nM = +44.5±11.1% (P < 0.05), and 100 nM = +67.5 + 15.8% (P < 0.05). Thus, pure 12-HETE was even more potent than the UV-generated mixture of HETE.
Effect ofcombining NSAID and HETE upon mucous glycoprotein release. In three separate experiments, NSAID (either ASA [100 ,tg/ml] or indomethacin [10 ,ug/ml]) were studied alone or in combination with HETE (Table VIII) . Each agent when studied alone enhanced the release of mucous glycoproteins. The combination of agents resulted in an additive effect in or * 50 100 10 ETYA MM FIGURE 1 The effect of ETYA on the release of mucous glycoproteins. ETYA (1-100 yM) was examined in 13 individual lung cultures. The results represent the mean percent decrease below control. *, P < 0.05; ***, P < 0.001. and failed to achieve statistical significance. PGE2, in contrast to all the other PG examined, consistently suppressed mucous release with a maximal effect at 1 ,uM. Indeed PGE2, the predominant PG produced by airways (12, 14) , was active at 0.01 ,uM (3.5 ng/ml), which is clearly within the physiologic range. In most organ systems, including the lung, AA is the predominant precursor of the naturally occurring PG (19, 20 (27) (28) (29) undergoing anaphylaxis. Slow-reacting substance is a mixture of leukotrienes derived from 5-hydroxy-arachidonic acid (30, 31) , indicating that human lung preparations contain lipoxygenase enzymes. ETYA inhibits fatty acid lipoxygenase and, in higher concentrations, cyclo-oxygenase as well (32) (33) (34) (35) . ETYA inhibited mucous release at concentrations above 10 ,M. In two experiments, 100 ,uM ETYA also inhibited both PGE and PGF2,, formation.
Arachidonic Acid Derivatives and Mucous Release
The decrease in mucous secretion produced by ETYA strengthened the suggestion that lipoxygenase products were responsible for increased mucous release. To further substantiate this suggestion, three additional inhibitors of the lipoxygenase enzyme system (NDGA, vitamin E, and a-naphthol; (21) were studied. All three antioxidants inhibited mucous release, NDGA did so in a dose-related fashion. NDGA also inhibited PGF2, and PGE synthesis.
A portion of AA added to human tissues is converted by specific lipoxygenases to unstable hydroperoxyeicosatetraenoic acids, which are transformed to HETE. The type and quantity of the HETE produced are specific to the cellular source. For example, human polymorphonuclear leukocytes synthesize 1 1-HETE, 8-HETE, and 5-D-HETE (18) , whereas platelets produce 12-HETE. Although the full spectrum of biological activities for these HETE has not been fully elucidated, 12-HETE is chemotactic for human polymorphonuclear leukocytes (36) and modulates other human neutrophil functions (37) . A role for lipoxygenase products in secretory reactions has been suggested by the inhibitory action of ETYA on mast cell secretion (15) as well as the capacity of several HETE to induce neutrophil degranulation under experimental conditions (38) . To examine the effect of HETE upon mucous release, a mixture of HETE was synthesized by UV irradiation of AA. The HETE synthesized included 5-, 8-, 11-, and 12-HETE although additional products were probably formed as well. The addition ofnanomolar concentrations ofthis mixture of HETE to airway cultures increased mucous release. As the mixture of HETE synthesized might have included sterioisomers to which airways may never be exposed, we also examined the effects of 12-HETE (1-100 nM). 12-HETE was even more potent than the mixture of HETE, having a significant action at 1 nM. We further tested the effect ofadding HETE to NSAID-treated airway cultures. Both NSAID, which may act to increase endogenous HETE formation, and the mixture of exogenously added HETE increased mucous release alone; in two out of three experiments, however, the combination of these agents acted in a synergistic fashion to increase mucous release. These data indicate that the addition of exogenous HETE increases mucous release and that pharmacologic manipulations resulting in alterations in HETE production may influence the release of mucus.
The clinical implications ofthese observations relate both to therapeutic approaches to states of excessive mucous production and to possible abnormalities in patients with aspirin-induced asthma. If the influence of HETE production noted in vitro applies to mucous production in vivo, antioxidants might present useful therapeutic agents for the treatment ofbronchorrhea. In much the same way, aspirin challenge of aspirin-sensitive asthmatic patients usually induces bronchorrhea and rhinorrhea which contribute to the airways' obstruction; it seems possible that aspirin-induced shifts of AA metabolism to the lipoxygenase pathway might be partly responsible for the bronchosecretory stimulus. It seems appropriate to study the modulation of HETE formation in vivo in humans in order to determine the effects of the agents on mucous secretion and their possible clinical implications.
